The Advantages and Disadvantages of Uterine Artery Embolization in Women with Adenomyosis: What’s New?

In: Current Obstetrics and Gynecology Reports · 2021 · vol. 10(4) , pp. 92–100 · doi:10.1007/s13669-021-00309-0 · W3201007300
article OA: closed CC0 ⤵ 1 in-corpus citation
Full text JSON View on OpenAlex View at publisher
AI-generated summary by claude@2026-06+body, 2026-06-13

Recent data indicate uterine artery embolization effectively reduces heavy bleeding and dysmenorrhea in adenomyosis patients, improving quality of life, but requires more randomized trials to confirm efficacy and durability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text

This review examines uterine artery embolization (UAE) as a conservative treatment for adenomyosis-associated abnormal uterine bleeding (AUB-A), drawing on data from 8 articles over the prior 5 years, including prospective and retrospective studies plus one systematic review and meta-analysis. Across included non-randomized evidence, UAE is reported to reduce heavy menstrual bleeding in about 80–88% of patients and dysmenorrhoea in 76–80%, with quality of life improvement and uterine volume reduction; a key limitation is the absence of randomized controlled trials and the predominance of retrospective designs. The review also lists potential disadvantages and adverse outcomes such as post-procedural pain, adenomyoma extrusion, pyomyoma, Asherman syndrome, and the possibility of further interventions including hysterectomy for persistent pain or bleeding. This paper is centrally about endometriosis and/or adenomyosis — it focuses on UAE for adenomyosis (AUB-A) and summarizes its advantages and disadvantages.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 9,317 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

Purpose of Review This review will examine the use of uterine artery embolization (UAE) for the management of adenomyosis (AUB-A) and evaluate its advantages and disadvantages. Recent Findings In the last 5 years, 8 articles have described UAE for the management of AUB-A. These include 2 prospective and 5 retrospective studies and 1 systematic review and meta-analysis. There are no randomised controlled trials for UAE as a treatment of adenomyosis. Recent data report a reduction in heavy menstrual bleeding (HMB) in 80–88% of patients and a reduction in dysmenorrhoea in 76–80% of those undergoing UAE. Quality of life is reported to be significantly improved and uterine volumes reduced following treatment. Disadvantages of UAE include post-procedural pain, adenomyoma extrusion, pyomyoma, Asherman syndrome, and requirement for further intervention including subsequent hysterectomy for management of pain or bleeding. Summary Initial non-randomised data support uterine artery embolization as an effective modality for the conservative management of AUB-A. The advantages of UAE include avoidance of abdominal surgery, significant improvement in symptoms, and quality of life scores and preservation of reproductive potential. To date, most data are retrospective with no randomised controlled studies and a few prospective analyses. Randomised controlled data are needed to comprehensively evaluate UAE as conservative treatment for AUB-A and to compare efficacy, cost, and durability of both medical and surgical treatments. Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance Bird CC, McElin TW, Manalo-Estrella P. The elusive adenomyosis of the uterus–revisited. Am J Obstet Gynecol. 1972;112(5):583–93. Stratopoulou CA, Donnez J, Dolmans MM. Origin and pathogenic mechanisms of uterine adenomyosis: what is known so far. Reprod Sci. 2021;28(8):2087–97. Munro MG, Critchley HOD, Fraser IS. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393–408. Lohle PNM, Higué D, Herbreteau D. Uterine artery embolisation in women with symptomatic adenomyosis. Presse Med. 2019;48(4):435–9. Donnez J, Donnez O, Dolmans MM. Introduction: uterine adenomyosis another enigmatic disease of our time. Fertil Steril. 2018;109(3):369–70. Abbott JA. Adenomyosis and abnormal uterine bleeding (AUB-A)-pathogenesis diagnosis and management. Best Pract Res Clin Obstet Gynaecol. 2017;40:68–81. Vercellini P, Parazzini F, Oldani S, Panazza S, Bramante T, Crosignani PG. Adenomyosis at hysterectomy: a study on frequency distribution and patient characteristics. Hum Reprod. 1995;10(5):1160–2. Di Donato N, Montanari G, Benfenati A, Leonardi D, Bertoldo V, Monti G, et al. Prevalence of adenomyosis in women undergoing surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2014;181:289–93. Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Res. 2019;8. Bergholt T, Eriksen L, Berendt N, Jacobsen M, Hertz JB. Prevalence and risk factors of adenomyosis at hysterectomy. Hum Reprod. 2001;16(11):2418–21. Bazot M, Cortez A, Darai E, Rouger J, Chopier J, Antoine J-M, et al. Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod. 2001;16(11):2427–33. Ravina JH, Herbreteau D, Ciraru-Vigneron N, Bouret JM, Houdart E, Aymard A, et al. Arterial embolisation to treat uterine myomata. Lancet. 1995;346(8976):671–2. D’Hoore T, Timmerman D, Laenen A, Maleux G. Long-term outcome and pre-interventional predictors for late intervention after uterine fibroid embolization. Eur J Obstet Gynecol Reprod Biol. 2020;247:149–55. Laughlin-Tommaso S, Barnard EP, AbdElmagied AM, Vaughan LE, Weaver AL, Hesley GK, et al. FIRSTT study: randomized controlled trial of uterine artery embolization vs focused ultrasound surgery. Am J Obstet Gynecol. 2019;220(2):174.e1-174.e13. Lacayo EA, Khera SS, Spies JB. Impact of patient and procedure-related factors on radiation exposure from uterine artery embolization. Cardiovasc Intervent Radiol. 2020;43(1):120–6. Han K, Kim SY, Kim HJ, Kwon JH, Kim GM, Lee J, et al. Nonspherical polyvinyl alcohol particles versus tris-acryl microspheres: randomized controlled trial comparing pain after uterine artery embolization for symptomatic fibroids. Radiology. 2021;298(2):458–65. Khayrutdinov E, Vorontsov I, Arablinskiy A, Shcherbakov D, Gromov D. A randomized comparison of transradial and transfemoral access in uterine artery embolization. Diagn Interv Radiol. 2021;27(1):59–64. Himiniuc LMM, Murarasu M, Toma B, Popovici R, Grigore AM, Scripcariu IS, et al. Transradial embolization, an underused type of uterine artery embolization approach: a systematic review. Medicina. 2021;57(2):83. Zhou J, He L, Liu P, Duan H, Zhang H, Li W, et al. Outcomes in adenomyosis treated with uterine artery embolization are associated with lesion vascularity: a long-term follow-up study of 252 cases. PLoS One. 2016;11(11):e0165610. • Liang E, Brown B, Rachinsky M. A clinical audit on the efficacy and safety of uterine artery embolisation for symptomatic adenomyosis: Results in 117 women. Aust N Z J Obstet Gynaecol. 2018;58(4):454–9. Findings in this study demonstrate symptom reduction and improved QoL scores at long-term follow-up. Wang S, Meng X, Dong Y. The evaluation of uterine artery embolization as a nonsurgical treatment option for adenomyosis. Int J Gynaecol Obstet. 2016;133(2):202–5. de Bruijn AM, Smink M, Lohle PNM, Huirne JAF, Twisk JWR, Wong C, et al. Uterine artery embolization for the treatment of adenomyosis: a systematic review and meta-analysis. J Vasc Interv Radiol. 2017;28(12):1629–42. Zheng R, Zeng D, Wan TT, Guo WB, Guo Y, Liu MJ. Predisposing factors for predicting the therapeutic response of adenomyosis after uterine artery embolization: serum CA125 levels and accompanying endometriosis. Diagn Interv Radiol. 2018;24(6):364–71. Guo W, Hu S, Zeng D, Yan C, Zheng R, Gao J, et al. The prognostic role of ovarian endometriosis in symptomatic adenomyosis patients underwent uterine artery embolization. Ann Palliat Med. 2021;10(3):2577–83. •• Wang Y, Lyu W, Xu W, Yu Y. Asherman syndrome in adenomyosis treated with uterine artery embolization: incidence predictive factors. Radiol Med. 2020;125(5):437–43. Findings in this study suggest that decreased lesion vascularity at the time of embolization increases the risk of subsequent intrauterine synechiae formation. Gynaecologists TRAaNZCoOa. Uterine artery embolisation for the treatment of uterine fibroids. C-Gyn 23. 2020. ACOG Committee Opinion. Uterine artery embolization. Obstet Gynecol. 2004;103(2):403–4. Dessouky R, Gamil SA, Nada MG, Mousa R, Libda Y. Management of uterine adenomyosis: current trends and uterine artery embolization as a potential alternative to hysterectomy. Insights Imaging. 2019;10(1):48. El Shamy T, Amer SAK, Mohamed AA, James C, Jayaprakasan K. The impact of uterine artery embolization on ovarian reserve: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2020;99(1):16–23. de Bruijn AM, Smink M, Hehenkamp WJK, Nijenhuis RJ, Smeets AJ, Boekkooi F, et al. Uterine artery embolization for symptomatic adenomyosis: 7-year clinical follow-up using UFS-Qol questionnaire. Cardiovasc Intervent Radiol. 2017;40(9):1344–50. Saibudeen A, Makris GC, Elzein A, Wigham A, Patel R, Husainy MA, et al. Pain management protocols during uterine fibroid embolisation: a systematic review of the evidence. Cardiovasc Intervent Radiol. 2019;42(12):1663–77. Kim SY, Koo BN, Shin CS, Ban M, Han K, Kim MD. The effects of single-dose dexamethasone on inflammatory response and pain after uterine artery embolisation for symptomatic fibroids or adenomyosis: a randomised controlled study. BJOG. 2016;123(4):580–7. Kim MD. Uterine artery embolization for leiomyomas and adenomyosis: a pictorial essay based on our experience from 1300 cases. Korean J Radiol. 2019;20(10):1462–73.

Acknowledgements

Thanks are given to Dr. Eisen Liang, Interventional Radiologist, Sydney Adventist Hospital, for the images presented in Fig. 1. Author information Authors and Affiliations Corresponding author Ethics declarations Conflict of Interest The authors declare no conflicts of interest relevant to this manuscript. Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors. Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This article is part of the Topical Collection on Uterine Fibroids and Endometrial Lesions Rights and permissions About this article Cite this article Knapman, B.L., Abbott, J. & Vyas, M.A. The Advantages and Disadvantages of Uterine Artery Embolization in Women with Adenomyosis: What’s New?. Curr Obstet Gynecol Rep 10, 92–100 (2021). https://doi.org/10.1007/s13669-021-00309-0 Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s13669-021-00309-0

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (32)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK